These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 16493232

  • 1. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R.
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN.
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [Abstract] [Full Text] [Related]

  • 10. Treatment of Alzheimer disease.
    Winslow BT, Onysko MK, Stob CM, Hazlewood KA.
    Am Fam Physician; 2011 Jun 15; 83(12):1403-12. PubMed ID: 21671540
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
    Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ.
    Arch Neurol; 2006 Jan 15; 63(1):49-54. PubMed ID: 16401736
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C.
    Eur J Health Econ; 2006 Jun 15; 7(2):137-44. PubMed ID: 16670912
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S, Wirth Y, Möbius HJ.
    Int J Geriatr Psychiatry; 2005 May 15; 20(5):459-64. PubMed ID: 15852444
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.